Article
Chloroquine efficacy for Plasmodium vivax in Myanmar in populations with high genetic diversity and moderate parasite gene flow.
Malaria journal - 10 Jul 2017
Htun Myo Win, Mon Nan Cho Nwe, Aye Khin Myo, Hlaing Chan Myae, Kyaw Myat Phone, Handayuni Irene, Trimarsanto Hidayat, Bustos Dorina, Ringwald Pascal, Price Ric N, Auburn Sarah, Thriemer Kamala
Abstract excerpt
BACKGROUND: Plasmodium vivax malaria remains a major public health burden in Myanmar. Resistance to chloroquine (CQ), the first-line treatment for P. vivax, has been reported in the country and has potential to undermine local control efforts. METHODS: Patients over 6 years of age with uncomplicated P. vivax mono-infection were enrolled into clinical efficacy studies in Myawaddy in 2014 and Kawthoung in 2012....
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.